Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylaxis for paclitaxel hypersensitivity reactions.

P E Kintzel1

  • 1Department of Pharmacy, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA. kintzelpe@aol.com

The Annals of Pharmacotherapy
|September 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticancer drug-induced kidney disorders.

Drug safety·2001
Same author

Symptomatic syndrome of inappropriate antidiuretic hormone secretion associated with azithromycin.

The Annals of pharmacotherapy·1998
Same author

Amphotericin B in fat emulsion.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1996
Same author

Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients.

The Annals of pharmacotherapy·1995
Same author

Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Cancer treatment reviews·1995
Same author

Otic administration of amphotericin B 0.25% in sterile water.

The Annals of pharmacotherapy·1994
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
See all related articles

Single-dose intravenous dexamethasone effectively prevents hypersensitivity reactions (HSRs) to paclitaxel infusions when combined with other medications. This approach offers a viable alternative for HSR prophylaxis in patients receiving paclitaxel.

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Pharmacovigilance

Background:

  • Paclitaxel is a widely used chemotherapy agent.
  • Hypersensitivity reactions (HSRs) are a significant concern during paclitaxel infusion.
  • Standard HSR prophylaxis often involves multiple doses of dexamethasone and other agents.

Purpose of the Study:

  • To review existing clinical literature on the efficacy of single-dose intravenous dexamethasone for preventing paclitaxel-induced HSRs.
  • To assess the role of single-dose dexamethasone as a prophylactic measure against paclitaxel hypersensitivity.

Main Methods:

  • A systematic review of clinical literature was conducted.
  • Literature search was performed using MEDLINE database.
  • Data retrieval spanned from 1986 to 2000.

Related Experiment Videos

Main Results:

  • Traditional prophylaxis involves multiple dexamethasone doses and pre-infusion medications (diphenhydramine, H2 antagonist).
  • Single-dose intravenous dexamethasone, administered with ancillary medications 30 minutes prior to paclitaxel, has been utilized.
  • This regimen has demonstrated effectiveness in preventing regimen-related HSRs.

Conclusions:

  • Single-dose intravenous dexamethasone is a feasible option for HSR prophylaxis.
  • This approach should be used in conjunction with appropriate ancillary medications.
  • It provides an effective strategy to mitigate paclitaxel-related hypersensitivity reactions.